Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Sanofi-a Ventis Deutschland Gmbh

Other

Sanofi

Roussel Uclaf

Sanofi-aventis

Hoechst Marion Roussel Deutschland Gmbh

Holger Heitsch

Adalbert Wagner

Klaus Wirth

Bernward Scholkens

Heinrich Christian Englert

Gabriele Wiemer

Heinz-Werner Kleemann

Wolfgang Linz

Stephanie Hachtel

Sven Grueneberg

Rainer Henning

Hermann J Gerhards

Stephen J Shimshock

Aleksandra Weichsel

Rosy Sher

Juergen Dedio

Heinz G&ouml;gelein

Gerhard Nolken

Raymond W Kosley, Jr

Hansjorg Urbach

Uwe Gerlach

Werngard Czechtizky

Hans-Willi Jansen

Christopher Kallus

Carolina Lanter

Bernward Sch&ouml;lkens

Heinz Gögelein

Hui Li

Martin Bickel

Volkmar Wehner

Jochen Knolle

Jean Buendia

Elisabeth Defossa

Gerhard Breipohl

Hans Jochen Lang

Reinhard Becker

Stephan Henke

Marcel Patek

Andreas Lindenschmidt

Max Hropot

Neerja Bhatnagar

Dieter Ruppert

Stefania Pfeiffer-Marek

Wolf-Ulrich Nickel

Christine Griffoul

Hauke Szillat

Heinz Goegelein

Hartmut R&uuml;tten

William Jerome Bock

Raymond Kosley

Helmut Bohn

Andrea Brüggemann

Andrea Brüggeman

Chung-Yi Kung

Charlie Chen

Bernward Sch Olkens

Karl-Heinz Lehr

Stephen Shimshock

Hui Sanofi-Aventis Us Inc Li

Stephen Sanofi-Aventis Us Inc Shimshock

The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.

Imidazole derivatives used as TAFIa inhibitors

The present invention relates to piperidinesulfonylureas and piperidinesulfonylthioureas of formula I, in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency, cardiomyopathies or reduced contractility of the heart or for the prevention of sudden cardiac death. The invention further relates to processes for preparing the compounds of formula I, their use and pharmaceutical compositions comprising them.

Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them

The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

CXCR2 inhibitors

The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

Imidazole derivatives as inhibitors of TAFIa

The present invention provides a process for identifying substances that modulate the activity of hyperpolarization-activated cation channels, and the use of this process.

Process for identifying substances which modulate the activity of hyperpolarization-activated cation channels

The invention relates to p-thienylbenzylamides of formula (I):in which R(1), R(2), R(3), R(4), R(5), R(6) and X have the meanings given in the description. The compounds of formula (I) are potent agonists of angiotensin-(1-7) receptors and are useful as pharmaceutically active compounds to treat and/or prevent hypertension; cardiac hypertrophy; cardiac insufficiency; coronary heart diseases, such as angina pectoris; and endothelial dysfunction or endothelial damage as a consequence, for example, of atherosclerotic processes or in association with diabetes mellitus.

P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparation and use

Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them

Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them

Inhibitors of the sodium-hydrogen exchanger are used for the production of a medicament for decreasing the undesired effects in human and in veterinary medicine which originate from substances which cause damage to the heart when administered acutely or chronically.

Use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substrates of the heart

1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them

Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptors blockers

Growing community of inventors

Mainz-Kastel, Germany

Holger Heitsch